Lyra Therapeutics (LYRA) Institutional Ownership $0.21 0.00 (-0.19%) (As of 11:57 AM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Lyra Therapeutics (NASDAQ:LYRA)CurrentInstitutional OwnershipPercentage95.62%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$19.69MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$8.31M Get LYRA Insider Trade Alerts Want to know when executives and insiders are buying or selling Lyra Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LYRA Institutional Buying and Selling by Quarter Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Lyra Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2024 State Street Corp488,720$126K0.0%+88.1%0.747% 8/6/2024 Acadian Asset Management LLC985,631$271K0.0%N/A1.617% 7/12/2024 Rosalind Advisors Inc.1,034,773$286K0.2%-9.6%1.697% 5/17/2024 Ikarian Capital LLC1,056,829$6.57M0.7%-15.7%1.733% 5/10/2024 Vanguard Group Inc.1,481,481$9.22M0.0%+38.3%2.430% 4/25/2024 Rosalind Advisors Inc.1,144,524$7.12M6.7%-39.4%1.916% Get the Latest News and Ratings for LYRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024 Parkman Healthcare Partners LLC754,885$3.96M0.6%+20.8%1.436% 2/14/2024 Vestal Point Capital LP3,000,000$15.72M1.7%N/A5.708% 2/13/2024 Armistice Capital LLC1,088,000$5.70M0.1%-29.8%2.070% 2/7/2024 Jump Financial LLC16,737$88K0.0%N/A0.032% 1/25/2024 Heritage Wealth Management Inc. Texas10,000$52K0.0%N/A0.019% 12/6/2023 Citigroup Inc.67,677$265K0.0%N/A0.129% 11/15/2023 Armistice Capital LLC1,550,000$6.06M0.1%-61.4%2.949% 11/14/2023 Prescott Group Capital Management L.L.C.30,000$117K0.0%N/A0.057% 10/24/2023 Bank of New York Mellon Corp18,621$73K0.0%N/A0.038% 8/24/2023 Perceptive Advisors LLC12,757,562$52.43M1.5%+39.5%25.747% 8/14/2023 Samsara BioCapital LLC2,780,261$11.43M2.0%+56.4%8.733% 8/14/2023 Pura Vida Investments LLC1,413,242$5.72M0.8%-29.2%4.439% 8/10/2023 Letko Brosseau & Associates Inc.31,900$131K0.0%N/A0.100% 2/15/2023 Nantahala Capital Management LLC2,220,830$6.97M0.5%-1.1%6.977% 2/14/2023 Pura Vida Investments LLC2,157,298$6.77M0.3%-14.1%6.778% 11/15/2022 Pura Vida Investments LLC2,510,302$12.58M0.7%-2.6%7.888% 11/14/2022 Boothbay Fund Management LLC34,721$174K0.0%-9.5%0.109% 11/10/2022 Nantahala Capital Management LLC2,245,830$11.25M0.7%-5.2%17.262% 8/16/2022 Pura Vida Investments LLC2,576,196$14.56M0.8%+394.9%19.802% 8/16/2022CVI Holdings LLC60,822$344K0.0%N/A0.468% 8/15/2022 Nantahala Capital Management LLC2,369,668$13.39M0.7%N/A18.214% 8/12/2022 Ensign Peak Advisors Inc56,229$318K0.0%+43.6%0.432% 8/12/2022 Ikarian Capital LLC347,338$1.96M0.4%-17.8%2.670% 5/16/2022 Clearline Capital LP119,924$482K0.1%+84.9%0.922% 2/14/2022 Clearline Capital LP64,862$283K0.0%N/A0.499% 2/14/2022 Soleus Capital Management L.P.10,000$44K0.0%-95.4%0.077% 2/11/2022 Pentwater Capital Management LP71,313$311K0.0%+122.8%0.548% 11/16/2021 Two Sigma Advisers LP58,000$529K0.0%+31.8%0.446% 11/15/2021 Pura Vida Investments LLC533,417$4.87M0.1%-1.7%4.103% 11/15/2021 Marshall Wace LLP12,457$114K0.0%-35.5%0.096% 11/9/2021BlackRock Inc.17,818$163K0.0%-11.4%0.137% 11/4/2021 Close Asset Management Ltd7,000$64K0.0%N/A0.054% 8/25/2021 Marshall Wace LLP19,321$155K0.0%-58.8%0.149% 8/18/2021 Ikarian Capital LLC624,684$5.02M0.4%-20.0%4.805% 3 Dirt-Cheap Stocks You Can’t Afford to Ignore (Ad)Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.Get your FREE look at these THREE companies right here.8/17/2021 Walleye Capital LLC19,093$153K0.0%N/A0.147% 8/17/2021 Millennium Management LLC155,135$1.25M0.0%N/A1.193% 8/17/2021 Bridgeway Capital Management LLC41,900$336K0.0%-14.5%0.322% 8/16/2021Tibra Equities Europe Ltd40,000$321K0.1%N/A0.308% 8/16/2021 Marshall Wace LLP19,321$155K0.0%-58.8%0.149% 8/13/2021 Geode Capital Management LLC36,102$289K0.0%-60.0%0.278% 8/13/2021 Vanguard Group Inc.220,029$1.77M0.0%+3.8%1.692% 8/12/2021 Trexquant Investment LP11,610$93K0.0%N/A0.089% 8/12/2021Ergoteles LLC31,000$249K0.0%N/A0.238% 8/11/2021 Deutsche Bank AG76,441$614K0.0%-5.4%0.588% 8/11/2021 Susquehanna International Group LLP21,529$173K0.0%N/A0.166% 8/2/2021 Advisor Group Holdings Inc.4,434$36K0.0%-89.6%0.034% 5/18/2021 Morgan Stanley107,217$1.24M0.0%+655.0%0.825% 5/17/2021 Nuveen Asset Management LLC17,913$208K0.0%N/A0.138% 5/17/2021 Ikarian Capital LLC780,728$9.05M0.3%-4.2%6.005% 5/13/2021 Bank of New York Mellon Corp15,036$174K0.0%-22.7%0.116% 5/13/2021 Blair William & Co. IL55,000$637K0.0%N/A0.424% 5/12/2021 Northern Trust Corp64,451$746K0.0%-5.2%0.497% 5/12/2021 Geode Capital Management LLC90,281$1.05M0.0%+31.8%0.696% 5/12/2021 JPMorgan Chase & Co.147,400$1.71M0.0%-22.8%1.137% 5/7/2021BlackRock Inc.348,394$4.04M0.0%+31.9%2.688% 5/4/2021 Envestnet Asset Management Inc.36,792$426K0.0%N/A0.284% 2/19/2021 JPMorgan Chase & Co.191,000$2.18M0.0%+9,858.3%1.478% 2/16/2021 Charles Schwab Investment Management Inc.14,177$162K0.0%N/A0.110% 2/13/2021 American International Group Inc.3,954$45K0.0%+60.9%0.031% 2/12/2021 Ikarian Capital LLC815,364$9.30M0.4%+110.2%6.307% 2/11/2021 Northern Trust Corp67,995$775K0.0%+39.1%0.526% 2/9/2021 Wells Fargo & Company MN3,521$40K0.0%+225.1%0.027% 2/9/2021 Bank of New York Mellon Corp19,450$222K0.0%+24.3%0.150% 2/5/2021BlackRock Inc.264,165$3.01M0.0%+27.4%2.044% 11/16/2020 ArrowMark Colorado Holdings LLC788,215$8.81M0.1%+293.8%6.097% 11/16/2020 Boothbay Fund Management LLC43,664$488K0.0%N/A0.338% 11/10/2020 State Street Corp45,506$509K0.0%+7.2%0.352% 11/6/2020BlackRock Inc.207,326$2.32M0.0%+1.0%1.604% 11/5/2020 New York State Common Retirement Fund4,438$50K0.0%-44.5%0.034% (Data available from 1/1/2016 forward) LYRA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LYRA shares? During the previous two years, 18 institutional investors and hedge funds held shares of Lyra Therapeutics. The most heavily invested institutionals were Perceptive Advisors LLC ($52.43M), Vestal Point Capital LP ($15.72M), Samsara BioCapital LLC ($11.43M), Vanguard Group Inc. ($9.22M), Nantahala Capital Management LLC ($6.97M), Ikarian Capital LLC ($6.57M), and Pura Vida Investments LLC ($5.72M).Learn more on LYRA's institutional investors. What percentage of Lyra Therapeutics stock is owned by institutional investors? 95.62% of Lyra Therapeutics stock is owned by institutional investors. Learn more on LYRA's institutional investor holdings. Which institutional investors have been buying Lyra Therapeutics stock? Of the 13 institutional investors that purchased Lyra Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Perceptive Advisors LLC ($3.61M), Vestal Point Capital LP ($3M), Samsara BioCapital LLC ($1.00M), Acadian Asset Management LLC ($985.63K), Vanguard Group Inc. ($410.02K), State Street Corp ($228.90K), and Parkman Healthcare Partners LLC ($129.83K). How much institutional buying is happening at Lyra Therapeutics? Institutional investors have bought a total of 9,543,158 shares in the last 24 months. This purchase volume represents approximately $38.97M in transactions. Which Lyra Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Lyra Therapeutics stock in the last 24 months: Armistice Capital LLC ($2.92M), Pura Vida Investments LLC ($936.73K), Rosalind Advisors Inc. ($853.95K), Ikarian Capital LLC ($197.56K), and Nantahala Capital Management LLC ($25K). How much institutional selling is happening at Lyra Therapeutics? Institutional investors have sold a total of 4,937,272 shares in the last 24 months. This volume of shares sold represents approximately $21.52M in transactions. Related Companies CTSO Institutional Ownership NXL Institutional Ownership CLGN Institutional Ownership NTRB Institutional Ownership MDAI Institutional Ownership COCH Institutional Ownership ICAD Institutional Ownership OM Institutional Ownership BLAC Institutional Ownership SURG Institutional Ownership This page (NASDAQ:LYRA) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
